Skip to main
VIGL
VIGL logo

Vigil Neuroscience (VIGL) Stock Forecast & Price Target

Vigil Neuroscience (VIGL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Vigil Neuroscience Inc is currently pursuing the development of therapeutics for neurodegenerative diseases, with its candidate VG-3927 demonstrating a favorable safety profile and target engagement, potentially supporting its once-daily dosing regimen. The company's commitment to utilizing biomarker data, specifically the nearly 50% dose-dependent reduction in TREM2 levels, indicates a strong engagement with target activity, which could substantiate the efficacy of their treatments. The ongoing study's comprehensive approach—incorporating blood/CSF biomarkers, imaging, and clinical outcomes—positions Vigil favorably for regulatory filing, which may enhance its market potential and support future growth in share value.

Bears say

Vigil Neuroscience has experienced significant pressure on its stock valuation, with shares declining by 26% following the recent ALEC TREM2 data readout, indicating growing investor concern. The company reported a net loss of $23.8 million in 4Q24 and a GAAP EPS of $(0.57), which fell short of analyst expectations, highlighting potential challenges in achieving commercial success. Additionally, the adjustment of the valuation discount rate to 35% resulted in a considerable reduction of the company’s target price from $24 to $13, raising further doubts about the stock's future performance amidst competitive pressures.

Vigil Neuroscience (VIGL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vigil Neuroscience (VIGL) Forecast

Analysts have given Vigil Neuroscience (VIGL) a Buy based on their latest research and market trends.

According to 8 analysts, Vigil Neuroscience (VIGL) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vigil Neuroscience (VIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.